Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

Go Back to All Clinical Trials

Phase 1b Multicenter Open-label Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

Brief description of study

To evaluate the safety and tolerability of RMC-6291 in combination with RMC-6236 in participants with KRASG12C-mutated solid tumors To estimate the MTD and/or RP2DS for RMC-6291 in combination with RMC-6236 in participants with KRASG12C-mutated solid tumors

Clinical Study Identifier: s24-00038

ClinicalTrials.gov Identifier: NCT06128551

Principal Investigator: Salman Rafi Punekar.

Other Investigators: Nina Beri, Samantha VanMaanen, Bhavana Pothuri, Jessica Wang, Michelle Diane Swanson Lightfoot, Elaine Shum, Paul E. Oberstein, Kristen Spencer, Joshua K Sabari, Keriann M Scavone, Yoke Wah Khoo, Kirby Rodriguez, Kathleen M Madden, Rajwanth Veluswamy, Nancy Chan, David R. Wise, Eneil De La Pena, Douglas K Marks.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies